Visual impairment

Prevent Blindness Declares March as Workplace Eye Wellness Month to Encourage Eye Safety Practices, Eye Protection at Work

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Computer, Social media, Workplace safety, Eye, American National Standards Institute, Visual impairment, Safety, Eye injury, Blue Light, Glare, Headache, GLARE, ANSI, Employment, Tablet, International, American Academy, Personal protective equipment

CHICAGO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has once again declared March as Workplace Eye Wellness Month to encourage employers and employees to make eye safety and eye protection a priority on the job. Prevent Blindness offers a variety of free resources including workplace eye safety fact sheets, shareable social media graphics in English and Spanish, and, to help employers educate workers on eye protection and safety, Prevent Blindness offers the Workplace Safety module in the Healthy Eyes Educational Series.

Key Points: 
  • Prevent Blindness Provides Free Resources on Eye Safety, Blue Light and Digital Eye Strain, and More, to Encourage Employers and Employees to Protect Eyes at Work
    CHICAGO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading eye health and safety nonprofit organization, has once again declared March as Workplace Eye Wellness Month to encourage employers and employees to make eye safety and eye protection a priority on the job.
  • Prevent Blindness offers a variety of free resources including workplace eye safety fact sheets , shareable social media graphics in English and Spanish, and, to help employers educate workers on eye protection and safety, Prevent Blindness offers the Workplace Safety module in the Healthy Eyes Educational Series .
  • Contact with objects or equipment led to the majority of eye injuries and illnesses requiring days away from work in 2020.
  • In the event of any eye injury, Prevent Blindness offers the " First Aid for Eye Emergencies " resource.

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Education, Medical director, Medical statistics, Parent, Infant, Pregnancy, University, Organization, Retinopathy, Diagnosis, Gestational age, Head, Social media, Section, Mental health, MBA, Associate professor, MSC, Initiative, Doctor of Psychology, Distribution, Partnership, FACS, National Eye Institute, Ear, University of Illinois Urbana-Champaign, Paratriathlon, ROP, Visual impairment, Safety, Division, MD, Visual Science, Diversity, Patient, Nursing

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

Actor & Advocate Marilee Talkington Receives 2024 Helen Keller Achievement Award

Retrieved on: 
Martedì, Febbraio 20, 2024
AC3, Disability, Multimedia, Education, Talkington, Morgan le Fay, Visual impairment, Perseverance, Organization, Journal, Helen Keller

WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- The American Foundation for the Blind (AFB) is pleased to announce actor Marilee Talkington will be among those to receive the prestigious Helen Keller Achievement Award, which AFB will present during a special evening ceremony on April 18th in Los Angeles.

Key Points: 
  • WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- The American Foundation for the Blind (AFB) is pleased to announce actor Marilee Talkington will be among those to receive the prestigious Helen Keller Achievement Award, which AFB will present during a special evening ceremony on April 18th in Los Angeles.
  • An acclaimed actor and activist for performers with disabilities, AFB recognizes Talkington for her continued contribution to breaking down barriers for people with disabilities in the performing arts.
  • Since 1994, the Helen Keller Achievement Award has recognized the finest thought leaders, change-makers, and performing artists committed to carrying on Keller's mission to create a world of full and equal inclusion for people with disabilities.
  • In addition to publishing the Journal of Visual Impairment & Blindness (JVIB), AFB is also the proud steward of the Helen Keller Archive on www.afb.org .

Foundation Fighting Blindness to honor Stephen Rappoport of L'Amy America and Noah Katz of PSK Supermarkets at the 2024 Night for Sight Gala in New York

Retrieved on: 
Giovedì, Febbraio 15, 2024
Supermarket, VM, Lighthouse, Next Generation, Marketing, Johnson & Johnson, Kid, Chelsea Piers, Hope, Food, Visual impairment, Pathmark, Retina, Paratriathlon, PSK, The Vision Council, Research, Partnership, Pharmaceutical industry

COLUMBIA, Md., Feb. 15, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, presents its prestigious Visionary Award to Stephen Rappoport, CEO of L'Amy America and Noah Katz, President and CEO of PSK Supermarkets through its annual gala, Night for Sight. Taking place on Thursday, May 9 at 6 p.m. ET at The Lighthouse at Chelsea Piers in Manhattan, Night for Sight will celebrate beacons of the fashion, food, and finance industries as well as the blindness community.

Key Points: 
  • The Foundation will honor Stephen Rappoport for his commitment to the vision community and leadership of one of the premier companies in the optical industry, L'Amy America.
  • The Foundation is also proud to honor Noah Katz for his dedication to the communities PSK Supermarkets serves.
  • "The Foundation Fighting Blindness is excited to honor Noah Katz and Stephen Rappoport through Night for Sight," said Jeff Klaas, chief strategy and innovation officer at the Foundation Fighting Blindness.
  • The Foundation thanks Visionary Champion National Partner, Johnson & Johnson, for their support of Night for Sight and Foundation Fighting Blindness events across the country.

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Opus, Drug development, University, IPO, Biomedicine, Vanderbilt University Medical Center, Biomedical engineering, Pharmacology, Genetics, American Diabetes Association, ARVO, Principal, NIH, Bank, Business development, Diabetic retinopathy, Therapy, Biomarker, Journal, Retina, Vanderbilt University, Biology, Discovery Medicine, Indiana University, OCUP, Roche, Visual impairment, Business, Diabetes, Paratriathlon, Economics, IND, Bank of America, Intelligence, FDA, Fortress Biotech, Doctor of Philosophy, Genentech, Insilico Medicine, Patient, Science, Editorial board, Citigroup, Pharmaceutical industry

FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Key Points: 
  • The team is now set and focused on executing our phase 3 program to turn our science into a reality for patients suffering from diabetic retinopathy, the leading cause of blindness in America.
  • I'm excited to work alongside such a talented team and together to take on significant unmet medical needs with compelling science.”
    Dr. Jayagopal added, “I am excited to join the talented Ocuphire team that has a successful track record in drug development and execution.
  • Prior to joining Ocuphire, he served as the Chief Scientific Officer of Opus Genetics.
  • In this role he had scientific and clinical leadership responsibility for Opus’ retinal gene therapy portfolio, including management of discovery, manufacturing, nonclinical development, and clinical development functions.

Foundation Fighting Blindness Hosting Webinar for Eye Care Professionals: Best Clinical Practices for Patients with Inherited Retinal Diseases

Retrieved on: 
Martedì, Febbraio 13, 2024
Therapy, Retinitis pigmentosa, Leber congenital amaurosis, Caregiver, Doctor of Philosophy, Ear, SCCO, University of Iowa, MD, Optometry, Brain damage, Genetic testing, University, Foundation Fighting Blindness, Visual impairment, Stargardt disease, Genetics, OD, Patient, IRD, Rehabilitation, Harvard Medical School, Marshall B. Ketchum University, Science, Usher syndrome, Research, Acquired brain injury, Nursing

COLUMBIA, Md., Feb. 13, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host a webinar for eye care professionals on the best practices for managing their patients with inherited retinal diseases (IRDs), including retinitis pigmentosa, Usher syndrome, Stargardt disease, and Leber congenital amaurosis. This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.

Key Points: 
  • This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.
  • "With nearly 50 clinical trials underway for emerging IRD therapies and no-cost genetic testing available for patients, eye care professionals can do so much to help IRD patients on their challenging journeys," says Michelle Glaze, director of professional outreach, Foundation Fighting Blindness.
  • "We are delighted to host this informative webinar to empower eye doctors to communicate hope and a path forward for their IRD patients and families."
  • She treats patients in the clinical departments of Acquired Brain Injury and Low Vision Rehabilitation, where she also conducts genetic testing for inherited eye conditions.

Filmmaker Shawn Levy Receives 2024 Helen Keller Achievement Award

Retrieved on: 
Giovedì, Febbraio 8, 2024
Helen Keller, Education, Disability, Visual impairment, Perception, Heart, Perseverance, Organization, Light, Multimedia, Nazism, Journal, Radio

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- The American Foundation for the Blind (AFB) is pleased to announce filmmaker Shawn Levy will be among those to receive the prestigious Helen Keller Achievement Award, which will be presented during a special evening ceremony on April 18th in Los Angeles.

Key Points: 
  • WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- The American Foundation for the Blind (AFB) is pleased to announce filmmaker Shawn Levy will be among those to receive the prestigious Helen Keller Achievement Award, which will be presented during a special evening ceremony on April 18th in Los Angeles.
  • The series was recently nominated for a Golden Globe, Directors Guild award, and Producers Guild award.
  • Since 1994, the Helen Keller Achievement Award has recognized the finest thought leaders, change-makers, and performing artists committed to carrying on Keller's mission to create a world of full and equal inclusion for people with disabilities.
  • For over 40 years, Helen Keller was AFB's leading ambassador, inspiring millions worldwide as she demonstrated all that can be accomplished through determination and perseverance.

Prevent Blindness Encourages Eye Safety for Upcoming Total Solar Eclipse in April

Retrieved on: 
Giovedì, Febbraio 8, 2024
Eclipse, Visual impairment, Diabetic retinopathy, UnitedHealth Group, ISO, International Organization (journal), Newsletter, Retina, NASA, Cell

CHICAGO, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, is preparing the public to safely experience the total solar eclipse that will take place on April 8th, 2024 with the Prevent Blindness Eclipse + Your Eyes program. The goal of the recently launched program is to educate the public on solar eclipses and raise awareness about the dangers of looking directly at the sun during an eclipse. The Eclipse + Your Eyes Program is made possible by the generous support of Silver Sponsors MyEyeDr. and National Vision, and Bronze Sponsors Amgen, UnitedHealthcare and VSP Vision.

Key Points: 
  • CHICAGO, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, is preparing the public to safely experience the total solar eclipse that will take place on April 8th, 2024 with the Prevent Blindness Eclipse + Your Eyes program.
  • Prevent Blindness wants to ensure all eyes are protected while doing so," said Jeff Todd, president and CEO of Prevent Blindness.
  • The eclipse on April 8th will be the last total solar eclipse visible from the contiguous United States until 2045.
  • Prevent Blindness wants to ensure all eyes are protected while doing so," said Jeff Todd, president and CEO of Prevent Blindness.

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

Retrieved on: 
Giovedì, Febbraio 8, 2024
Alimera Sciences, Visual impairment, NHS Wales, News, Patient, Recurrence, Physician, NHS, Disease, Fluocinolone acetonide, DME, NHS England, Pharmaceutical industry

“This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Key Points: 
  • “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • We look forward to the publication of Final Guidance shortly.”
    NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes.
  • NHS England has agreed with the Integrated Care Boards (ICB’s) to provide funding to implement this guidance 30 days after publication.
  • NHS Wales will usually fund within 2 months of the final draft guidance.

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Retrieved on: 
Mercoledì, Febbraio 7, 2024
Visual impairment, European, Deficit spending, International, Polydactyly, Obesity, POMC, LEPR, Patient, Prevalence, BBS, Polyphagia, Gazzetta Ufficiale, Rhythm, Hunger, Medicine, MC4R, PCSK1, Bardet–Biedl syndrome, Hypogonadism, Pharmaceutical industry

“We are pleased that AIFA has recognized the need for a precision medicine for obesity and control of hunger in BBS,” said Yann Mazabraud, Executive Vice President and Head of International at Rhythm.

Key Points: 
  • “We are pleased that AIFA has recognized the need for a precision medicine for obesity and control of hunger in BBS,” said Yann Mazabraud, Executive Vice President and Head of International at Rhythm.
  • BBS is also associated with cognitive impairment, polydactyly, renal dysfunction, hypogonadism, and visual impairment.
  • In Italy, the Company estimates the prevalence of BBS to be between 1/125,000 and 1/160,000, with approximately 200 identified.
  • AIFA previously approved reimbursement for IMCIVREE for the treatment of obesity and control of hunger associated with biallelic proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or biallelic leptin receptor (LEPR) deficiency.